Pipeline
Molecules in Clinical Development
Targeted Therapy
Immunotherapy
ADC
The molecules presented are investigational. Safety and efficacy have not been established.
TARGET
TUMOR TYPE
PHASE
SI-B001
Target:
EGFRxHER3
Epithelial Tumors
P1
Non-Small Cell Lung Cancer
P2
Esophageal Squamous Cell Carcinoma
P2
Head and Neck Squamous Cell Carcinoma
P2
SI-B003
Target:
CTLA-4xPD-1
Solid Tumor
P1
Esophageal Squamous Cell Carcinoma
P2
GNC-035
Target:
ROR1×PD-L1×4-1BB×CD3
Breast Cancer
P1
Hematologic Malignancies
P1
GNC-038
Target:
CD19×PD-L1×4-1BB×CD3
Primaryand Secondary CNS Lymphomas
P2
Diffuse Large B-Cell Lymphoma
P2
Non-Hodgkin Lymphoma
P2
GNC-039
Target:
EGFRvIII×PD-L1×4-1BB×CD3
Glioma
P1
BL-B01D1
Target:
EGFRxHER3
Solid Tumors
P1
Breast Cancer
P1
Urinary Tract Tumors
P2
Gastrointestinal Tumors
P1
Gynecological Tumors
P1
Non-Small Cell Lung Cancer
P2
BL-M02D1
Target:
Trop2
Gastrointestinal Tumors
P1
Triple Negative Breast Cancer
P1
BL-M07D1
Target:
HER2
Breast Cancer
P1
Digestive Tract Tumors
P1
BL-M11D1
Target:
CD33
Acute Myeloid Leukemia
P1
Research & Development
